Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew Tutt, Doctor of Medicine
Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK
Principal Investigator - Charles Geyer, Doctor of Medicine
Virginia Commonwealth University Massey Cancer Center, McGlothlin Medical Education Center, Room 12-217, 1201 East Marshall St., PO Box 980070, Richmond, VA 23298-0070, USA
Principal Investigator - Judy Garber, Doctor of Medicine
Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Susan F. Smither Center for Women's Cancers, 450 Brookline Avenue, Boston; MA 02215, US
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
698 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Berazategui, Argentina
- Research Site
CABA, Argentina
- Research Site
CABA, Argentina
- Research Site
Córdoba, Argentina
- Research Site
Córdoba, Argentina
- Research Site
La Rioja, Argentina
- Research Site
Mendoza, Argentina
- Research Site
Rosario, Argentina
- Research Site
San Miguel de Tucumán, Argentina
- Research Site
Santa Fe, Argentina
- Research Site
Adelaide, Australia
- Research Site
Auchenflower, Australia
- Research Site
Concord, Australia
- Research Site
Douglas, Australia
- Research Site
Gosford, Australia
- Research Site
Hobart, Australia
- Research Site
Malvern, Australia
- Research Site
Melbourne, Australia
- Research Site
Nedlands, Australia
- Research Site
Randwick, Australia
- Research Site
South Brisbane, Australia
- Research Site
Tamworth, Australia
- Research Site
Tweed Heads, Australia
- Research Site
Waratah, Australia
- Research Site
Wendouree, Australia
- Research Site
Graz, Austria
- Research Site
Innsbruck, Austria
- Research Site
Leoben, Austria
- Research Site
Linz, Austria
- Research Site
Linz, Austria
- Research Site
Rankweil, Austria
- Research Site
Ried, Austria
- Research Site
Salzburg, Austria
- Research Site
Sankt Veit an der Glan, Austria
- Research Site
Vienna, Austria
- Research Site
Vienna, Austria
- Research Site
Vienna, Austria
- Research Site
Villach, Austria
- Research Site
Vöcklabruck, Austria
- Research Site
Weiz, Austria
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Apr 2014
- Primary completion
- 27 Mar 2020
- Completion
- 28 May 2029
- Last update posted
- 6 May 2026
- Registered enrollment
- 1,837
- Registry id
- NCT02032823
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.